

ORIGINAL FILED  
COPY OF PAPERS

RCE/1600

|  |                                  |                       |                             |  |
|--|----------------------------------|-----------------------|-----------------------------|--|
| AMENDMENT TRANSMITTAL LETTER   |                                  |                       | DOCKET NUMBER:<br>P-IX 2947 |  |
| SERIAL NO:<br>09/203,768   | FILING DATE:<br>December 2, 1998 | EXAMINER:<br>L. Helms | GROUP ART UNIT:<br>1642     |  |
| INVENTION: TUMOR SPECIFIC HUMAN MONOCLONAL ANTIBODIES AND METHODS OF USE |                                  |                       |                             |  |

TO COMMISSIONER FOR PATENTS  
ATTN: Box RCE

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Attention Box RCE, Washington, D.C., 20231 on April 5, 2002.

By: John T. Murphy  
John T. Murphy, Reg. No. 50,583  
April 5, 2002  
Date of Signature

Transmitted herewith is a Request for Continued Examination in response to the Office Action mailed January 25, 2002, and the final Office Action mailed May 3, 2001, (in duplicate) in the above-identified application.

- ☒ Small Entity status of this application has been established under 37 CFR 1.27.
- ☒ Petition for Extension of Time is enclosed (in duplicate).
- ☒ Response to Advisory Action mailed January 25, 2002, and the final Office Action mailed May 3, 2001, with attached Appendix A is enclosed.
- ☒ No additional claims fee is required.

CLAIMS AS AMENDED

|  | NUMBER AFTER AMENDMENT |   | HIGHEST NUMBER PREVIOUSLY PAID FOR |   | NUMBER OF EXTRA CLAIMS PRESENTED |    | RATE                 |              |   | FEE          |              |
|--|------------------------|---|------------------------------------|---|----------------------------------|----|----------------------|--------------|---|--------------|--------------|
|  |                        |   |                                    |   |                                  |    | SMALL ENTITY         | OTHER ENTITY |   | SMALL ENTITY | OTHER ENTITY |
| TOTAL CLAIMS                                   | 48                     | - | 48                                 | - | 0                                | x  | \$9                  | \$18         | = | \$0          | \$           |
| INDEPENDENT CLAIMS                             | 14                     | - | 14                                 | - | 0                                | x  | \$42                 | \$84         | = | \$0          | \$           |
| FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM |                        |   | YES                                |   | X                                | NO | \$140                | \$280        | = | \$0          | \$           |
|  |                        |   |                                    |   |                                  |    | TOTAL ADDITIONAL FEE |              |   | \$0          | \$           |

\* If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.

\*\* If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.

\*\*\* If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 0, write "0" in the space.

\_\_\_\_ Please charge my Deposit Account No. 03-0370 the amount of \$\_\_\_\_. A duplicate copy of this sheet is enclosed.

RECEIVED  
APR 19 2002  
TECH CENTER 1600/2900


#  
21  
160  
4-30-02

Inventors: Watkins and Huse  
Serial No.: 09/203,768  
Filed: December 2, 1998  
Page 2

- X A check in the amount of \$830.00 is enclosed, \$370.00 of which covers the request for continued examination fee under 37 C.F.R. § 1.17(e) and \$460.00 of which covers the fee for a three-month extension of time.
- X The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 03-0370. A duplicate copy of this sheet is enclosed.
- X Any additional filing fees required under 37 C.F.R. 1.16.
- X Any patent application processing fees under 37 C.F.R. 1.17.
- X The Commissioner is hereby authorized to charge to Deposit Account No. 03-0370 any fees under 37 CFR 1.17 which may be required under 37 CFR 1.136(a)(3) for an extension of time in any concurrent or future reply requiring a petition for extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

April 5, 2002  
Date

  
\_\_\_\_\_  
John T. Murphy  
Registration No. 50,583  
CAMPBELL & FLORES LLP  
4370 La Jolla Village Drive  
7<sup>th</sup> Floor  
San Diego, California 92122  
858-535-9001  
USPTO CUSTOMER NO. 23601

RECEIVED


APR 19 2002

TECH CENTER 1600/2900

PATENT

Our Docket: P-IX 2947

COPY OF PAPERS  
ORIGINALLY FILED



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of  
Watkins and Huse

Serial No.: 09/203,768

Filed: December 2, 1998

For: TUMOR SPECIFIC HUMAN  
MONOCLONAL ANTIBODIES  
AND METHODS OF USE

) Group Art Unit: 1642

) Examiner: L. Helms

) I hereby certify that this correspondence  
) is being deposited with the United States  
) Postal Service as first class mail in an  
) envelope addressed to: Commissioner for  
) Patents, Attention Box RCE, Washington,  
) D.C., 20231, on April 5, 2002.

By John T. Murphy Reg. No. 50,583

April 5, 2002  
Date of Signature

Box RCE

Commissioner for Patents  
Washington, D.C. 20231

REQUEST FOR CONTINUED EXAMINATION

This is a request for continued examination of the  
above-identified application. 37 C.F.R. § 1.114.

At least one of the following submissions is being  
filed herewith:

- ☒ Amendment or Response  
☐ Declaration or Affidavit  
☐ Information Disclosure Statement

A check in the amount of \$830.00 is being filed  
herewith, \$370.00 of which covers the request for continued  
examination fee under 37 C.F.R. § 1.17(e) and \$460.00 of which  
covers the fee for a three-month extension of time.


Inventors: Watkins and Huse  
Serial No.: 09/203,768  
Filed: December 2, 1998  
Page 2

The Director is hereby authorized to charge payment or credit any overpayment to Deposit Account No. 03-0370 for any of the following fees: additional filing fees under 37 C.F.R. § 1.16, patent application processing fees under 37 C.F.R. § 1.17, or any fees under 37 C.F.R. § 1.17 that may be required under 37 C.F.R. § 1.136(a)(3) for an extension of time in any concurrent or future reply requiring a petition for extension of time. A duplicate copy of this sheet is enclosed for this purpose.

Accordingly, the Applicants respectfully request withdrawal of the finality of the outstanding office action, and consideration of the submission filed herewith. The Examiner is invited to call the undersigned agent or Cathryn Campbell with any questions.

Respectfully submitted,

April 5, 2002  
Date

  
\_\_\_\_\_  
John T. Murphy  
Registration No. 50,583  
Telephone No. (858) 535-9001  
Facsimile No. (858) 535-8949

CAMPBELL & FLORES LLP  
4370 La Jolla Village Drive  
7th Floor  
San Diego, California 92122  
USPTO CUSTOMER NO. 23601

RECEIVED


APR 19 2002

TECH CENTER 1600/2900

PATENT

Our Docket: P-IX 2947

COPY OF PAPERS  
ORIGINALLY FILED



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of  
Watkins and Huse

Serial No.: 09/203,768

Filed: December 2, 1998

For: TUMOR SPECIFIC HUMAN  
MONOCLONAL ANTIBODIES  
AND METHODS OF USE

) Group Art Unit: 1642

) Examiner: L. Helms

) I hereby certify that this correspondence  
) is being deposited with the United States  
) Postal Service as first class mail in an  
) envelope addressed to: Commissioner for  
) Patents, Attention Box RCE, Washington,  
) D.C., 20231, on April 5, 2002.

) By John T. Murphy, Reg. No. 50,583

) April 5, 2002  
) Date of Signature

Box RCE

Commissioner for Patents  
Washington, D.C. 20231

RESPONSE TO OFFICE ACTION

Responsive to the Advisory Action mailed  
January 25, 2002, and the final Office Action mailed May 3, 2001,  
entry of the following amendments and remarks is respectfully  
requested.

AMENDMENTS

1. (Thrice amended) A human monoclonal antibody or  
functional fragment thereof, comprising the amino acid sequence  
of SEQ ID NO:2, or having a conservative substitution of an amino  
acid thereof, and the amino acid sequence of SEQ ID NO:4, or  
having a conservative substitution of an amino acid thereof,  
wherein said antibody or functional fragment thereof binds a  
neoplastic cell or antigen thereof.